tov 21g  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    ATCC tov 21g
    Ovarian cancer cell lines exhibit varied responses to paclitaxel treatment. Paclitaxel-resistant (PacR) and parental control ovarian cancer cell lines, <t>TOV-21G</t> and OVCAR3, were treated with serially diluted doses of paclitaxel for 96 hours in vitro . Cell viability is displayed at each concentration tested relative to untreated cells for the control (black) and PacR (red) cell lines of (A) TOV-21G and (B) OVCAR3 cells. Dose response curves were fit to the data and IC 50 values were calculated using four-parameter log-logistic models. (C) Ovarian tumor organoid cell lines’ paclitaxel EC 50 values. Resistant lines are shown in gold and sensitive lines are shown in black.
    Tov 21g, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tov 21g/product/ATCC
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    tov 21g - by Bioz Stars, 2022-10
    96/100 stars

    Images

    1) Product Images from "Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer"

    Article Title: Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0254205

    Ovarian cancer cell lines exhibit varied responses to paclitaxel treatment. Paclitaxel-resistant (PacR) and parental control ovarian cancer cell lines, TOV-21G and OVCAR3, were treated with serially diluted doses of paclitaxel for 96 hours in vitro . Cell viability is displayed at each concentration tested relative to untreated cells for the control (black) and PacR (red) cell lines of (A) TOV-21G and (B) OVCAR3 cells. Dose response curves were fit to the data and IC 50 values were calculated using four-parameter log-logistic models. (C) Ovarian tumor organoid cell lines’ paclitaxel EC 50 values. Resistant lines are shown in gold and sensitive lines are shown in black.
    Figure Legend Snippet: Ovarian cancer cell lines exhibit varied responses to paclitaxel treatment. Paclitaxel-resistant (PacR) and parental control ovarian cancer cell lines, TOV-21G and OVCAR3, were treated with serially diluted doses of paclitaxel for 96 hours in vitro . Cell viability is displayed at each concentration tested relative to untreated cells for the control (black) and PacR (red) cell lines of (A) TOV-21G and (B) OVCAR3 cells. Dose response curves were fit to the data and IC 50 values were calculated using four-parameter log-logistic models. (C) Ovarian tumor organoid cell lines’ paclitaxel EC 50 values. Resistant lines are shown in gold and sensitive lines are shown in black.

    Techniques Used: In Vitro, Concentration Assay

    Differential regulation of ABCB1 expression by EGFR in ovarian cancer cell lines. (A) Dose response curves following siRNA knockdown of EGFR, ERBB2 or ERBB4 in TOV-21G-control and–PacR cells indicating cell viability after 96 hours of exposure to paclitaxel. (B) Paclitaxel IC50 in OVCAR3-control and -PacR cells following knock-down of EGFR, ERBB2, and ERBB4 expression. Bar plots depict average IC50 +/- standard error of the mean (SEM). ANOVA p
    Figure Legend Snippet: Differential regulation of ABCB1 expression by EGFR in ovarian cancer cell lines. (A) Dose response curves following siRNA knockdown of EGFR, ERBB2 or ERBB4 in TOV-21G-control and–PacR cells indicating cell viability after 96 hours of exposure to paclitaxel. (B) Paclitaxel IC50 in OVCAR3-control and -PacR cells following knock-down of EGFR, ERBB2, and ERBB4 expression. Bar plots depict average IC50 +/- standard error of the mean (SEM). ANOVA p

    Techniques Used: Expressing

    ABCB1 overexpression is sufficient for paclitaxel resistance in ovarian cancer. Cell viability following paclitaxel treatment was examined after silencing ABCB1 expression in TOV-21G and OVCAR3 cells. IC 50 values were compared across non-target siRNA (siNTC) and ABCB1 siRNA (siABCB1) transfected cells using unpaired two-tailed t-tests. * p
    Figure Legend Snippet: ABCB1 overexpression is sufficient for paclitaxel resistance in ovarian cancer. Cell viability following paclitaxel treatment was examined after silencing ABCB1 expression in TOV-21G and OVCAR3 cells. IC 50 values were compared across non-target siRNA (siNTC) and ABCB1 siRNA (siABCB1) transfected cells using unpaired two-tailed t-tests. * p

    Techniques Used: Over Expression, Expressing, Transfection, Two Tailed Test

    Lapatinib and poziotinib demonstrate anti-proliferative synergy when combined with paclitaxel. (A) A panel of TKIs were screened for anti-proliferative synergy when combined with paclitaxel on TOV-21G-control and–PacR derivative cell lines. The ABCB1-specific inhibitor, elacridar, was included as a positive control. Average Bliss synergy scores across drug combinations (minimum of 3 independent experiments) are summarized as averages +/- standard error of the mean. Unpaired two-tailed t-tests were performed for each drug (control vs. PacR; * p
    Figure Legend Snippet: Lapatinib and poziotinib demonstrate anti-proliferative synergy when combined with paclitaxel. (A) A panel of TKIs were screened for anti-proliferative synergy when combined with paclitaxel on TOV-21G-control and–PacR derivative cell lines. The ABCB1-specific inhibitor, elacridar, was included as a positive control. Average Bliss synergy scores across drug combinations (minimum of 3 independent experiments) are summarized as averages +/- standard error of the mean. Unpaired two-tailed t-tests were performed for each drug (control vs. PacR; * p

    Techniques Used: Positive Control, Two Tailed Test

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96
    ATCC tov 21g
    Ovarian cancer cell lines exhibit varied responses to paclitaxel treatment. Paclitaxel-resistant (PacR) and parental control ovarian cancer cell lines, <t>TOV-21G</t> and OVCAR3, were treated with serially diluted doses of paclitaxel for 96 hours in vitro . Cell viability is displayed at each concentration tested relative to untreated cells for the control (black) and PacR (red) cell lines of (A) TOV-21G and (B) OVCAR3 cells. Dose response curves were fit to the data and IC 50 values were calculated using four-parameter log-logistic models. (C) Ovarian tumor organoid cell lines’ paclitaxel EC 50 values. Resistant lines are shown in gold and sensitive lines are shown in black.
    Tov 21g, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tov 21g/product/ATCC
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    tov 21g - by Bioz Stars, 2022-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    Ovarian cancer cell lines exhibit varied responses to paclitaxel treatment. Paclitaxel-resistant (PacR) and parental control ovarian cancer cell lines, TOV-21G and OVCAR3, were treated with serially diluted doses of paclitaxel for 96 hours in vitro . Cell viability is displayed at each concentration tested relative to untreated cells for the control (black) and PacR (red) cell lines of (A) TOV-21G and (B) OVCAR3 cells. Dose response curves were fit to the data and IC 50 values were calculated using four-parameter log-logistic models. (C) Ovarian tumor organoid cell lines’ paclitaxel EC 50 values. Resistant lines are shown in gold and sensitive lines are shown in black.

    Journal: PLoS ONE

    Article Title: Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

    doi: 10.1371/journal.pone.0254205

    Figure Lengend Snippet: Ovarian cancer cell lines exhibit varied responses to paclitaxel treatment. Paclitaxel-resistant (PacR) and parental control ovarian cancer cell lines, TOV-21G and OVCAR3, were treated with serially diluted doses of paclitaxel for 96 hours in vitro . Cell viability is displayed at each concentration tested relative to untreated cells for the control (black) and PacR (red) cell lines of (A) TOV-21G and (B) OVCAR3 cells. Dose response curves were fit to the data and IC 50 values were calculated using four-parameter log-logistic models. (C) Ovarian tumor organoid cell lines’ paclitaxel EC 50 values. Resistant lines are shown in gold and sensitive lines are shown in black.

    Article Snippet: Resistant cell lines exhibited increases in paclitaxel IC50 ranging from 6.5-fold for OVCAR3 (26.6 nM in resistant versus 4.1 nM in control) to 94-fold for TOV-21G (403.1 nM in resistant versus 4.3 nM in control) ( ).

    Techniques: In Vitro, Concentration Assay

    Differential regulation of ABCB1 expression by EGFR in ovarian cancer cell lines. (A) Dose response curves following siRNA knockdown of EGFR, ERBB2 or ERBB4 in TOV-21G-control and–PacR cells indicating cell viability after 96 hours of exposure to paclitaxel. (B) Paclitaxel IC50 in OVCAR3-control and -PacR cells following knock-down of EGFR, ERBB2, and ERBB4 expression. Bar plots depict average IC50 +/- standard error of the mean (SEM). ANOVA p

    Journal: PLoS ONE

    Article Title: Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

    doi: 10.1371/journal.pone.0254205

    Figure Lengend Snippet: Differential regulation of ABCB1 expression by EGFR in ovarian cancer cell lines. (A) Dose response curves following siRNA knockdown of EGFR, ERBB2 or ERBB4 in TOV-21G-control and–PacR cells indicating cell viability after 96 hours of exposure to paclitaxel. (B) Paclitaxel IC50 in OVCAR3-control and -PacR cells following knock-down of EGFR, ERBB2, and ERBB4 expression. Bar plots depict average IC50 +/- standard error of the mean (SEM). ANOVA p

    Article Snippet: Resistant cell lines exhibited increases in paclitaxel IC50 ranging from 6.5-fold for OVCAR3 (26.6 nM in resistant versus 4.1 nM in control) to 94-fold for TOV-21G (403.1 nM in resistant versus 4.3 nM in control) ( ).

    Techniques: Expressing

    ABCB1 overexpression is sufficient for paclitaxel resistance in ovarian cancer. Cell viability following paclitaxel treatment was examined after silencing ABCB1 expression in TOV-21G and OVCAR3 cells. IC 50 values were compared across non-target siRNA (siNTC) and ABCB1 siRNA (siABCB1) transfected cells using unpaired two-tailed t-tests. * p

    Journal: PLoS ONE

    Article Title: Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

    doi: 10.1371/journal.pone.0254205

    Figure Lengend Snippet: ABCB1 overexpression is sufficient for paclitaxel resistance in ovarian cancer. Cell viability following paclitaxel treatment was examined after silencing ABCB1 expression in TOV-21G and OVCAR3 cells. IC 50 values were compared across non-target siRNA (siNTC) and ABCB1 siRNA (siABCB1) transfected cells using unpaired two-tailed t-tests. * p

    Article Snippet: Resistant cell lines exhibited increases in paclitaxel IC50 ranging from 6.5-fold for OVCAR3 (26.6 nM in resistant versus 4.1 nM in control) to 94-fold for TOV-21G (403.1 nM in resistant versus 4.3 nM in control) ( ).

    Techniques: Over Expression, Expressing, Transfection, Two Tailed Test

    Lapatinib and poziotinib demonstrate anti-proliferative synergy when combined with paclitaxel. (A) A panel of TKIs were screened for anti-proliferative synergy when combined with paclitaxel on TOV-21G-control and–PacR derivative cell lines. The ABCB1-specific inhibitor, elacridar, was included as a positive control. Average Bliss synergy scores across drug combinations (minimum of 3 independent experiments) are summarized as averages +/- standard error of the mean. Unpaired two-tailed t-tests were performed for each drug (control vs. PacR; * p

    Journal: PLoS ONE

    Article Title: Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

    doi: 10.1371/journal.pone.0254205

    Figure Lengend Snippet: Lapatinib and poziotinib demonstrate anti-proliferative synergy when combined with paclitaxel. (A) A panel of TKIs were screened for anti-proliferative synergy when combined with paclitaxel on TOV-21G-control and–PacR derivative cell lines. The ABCB1-specific inhibitor, elacridar, was included as a positive control. Average Bliss synergy scores across drug combinations (minimum of 3 independent experiments) are summarized as averages +/- standard error of the mean. Unpaired two-tailed t-tests were performed for each drug (control vs. PacR; * p

    Article Snippet: Resistant cell lines exhibited increases in paclitaxel IC50 ranging from 6.5-fold for OVCAR3 (26.6 nM in resistant versus 4.1 nM in control) to 94-fold for TOV-21G (403.1 nM in resistant versus 4.3 nM in control) ( ).

    Techniques: Positive Control, Two Tailed Test